Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.
EBioMedicine
; 75: 103811, 2022 Jan.
Article
in En
| MEDLINE
| ID: mdl-35042081
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunogenicity, Vaccine
/
COVID-19 Vaccines
/
Genetic Vectors
/
SARS-CoV-2
/
COVID-19
/
Measles virus
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
EBioMedicine
Year:
2022
Document type:
Article
Affiliation country:
Belgium
Country of publication:
Netherlands